Drug intelligence / Profile preview

vidarabine monophosphate

Development stage
Unknown
Lead developer
Kaifeng Mingren Pharma
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Vidarabine monophosphate is a small molecule nucleoside analog antiviral agent developed and marketed by Kaifeng Pharma (Kaifeng Mingren Pharmaceutical Co., Ltd.). It is the monophosphate derivative of vidarabine (adenine arabinoside), designed to provide significantly improved water solubility compared to the parent compound, which facilitates its administration as an injection. The drug acts as a prodrug that is intracellularly converted into its active triphosphate form. Once activated, it competitively inhibits viral DNA polymerase, thereby interfering with viral DNA synthesis and replication. In China, it is approved and marketed as a freeze-dried powder for injection for the treatment of various herpes virus infections, including herpes simplex encephalitis, cutaneous and mucosal herpes, and varicella-zoster virus infections.

Other names
adenine arabinoside monophosphateAra-AMP单磷酸阿糖腺苷注射用单磷酸阿糖腺苷
02

Targets

HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))DNTT (Terminal deoxynucleotidyl transferase)RNR (Ribonucleotide reductase)Herpesvirus DNA polymerasePOLB (DNA polymerase beta)HSV DNA pol (Herpes simplex virus DNA polymerase)POLA1 (DNA polymerase alpha)

Beyond the preview

Go deeper on vidarabine monophosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vidarabine monophosphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call